癌症的基本特征包括细胞增殖、血管生成、迁移、凋亡逃避机制和细胞永生等。找到癌症发生过程中这些通路的关键标记物和对应的抗体用于检测至关重要。
为您推荐一个泛素化位点预测神器——泛素化分析工具，可以为您的蛋白的泛素化位点作出预测和评分。
细胞自噬受体图形绘图工具为你的蛋白的细胞受体结合位点作出预测和评分，识别结合到自噬通路中的蛋白是非常重要的，便于让我们理解自噬在正常生理、病理过程中的作用，如发育、细胞分化、神经退化性疾病、压力条件下、感染和癌症。
Anti-NuSAP Antibody
- 产品详情
- 实验流程
Application 
| WB |
|---|---|
| Primary Accession | Q9BXS6 |
| Reactivity | Human, Mouse, Rat, Bovine, Dog |
| Host | Rabbit |
| Clonality | Polyclonal |
| Calculated MW | 49452 Da |
| Gene ID | 51203 |
|---|---|
| Other Names | ANKT; Nucleolar and spindle-associated protein 1; NuSAP |
| Target/Specificity | KLH-conjugated synthetic peptide encompassing a sequence within the C-term region of human NuSAP. The exact sequence is proprietary. |
| Dilution | WB~~WB (1/500 - 1/1000) |
| Format | Liquid in 0.42% Potassium phosphate, 0.87% Sodium chloride, pH 7.3, 30% glycerol, and 0.01% sodium azide. |
| Storage | Store at -20 °C.Stable for 12 months from date of receipt |
For Research Use Only. Not For Use In Diagnostic Procedures.
| Name | NUSAP1 |
|---|---|
| Synonyms | ANKT |
| Function | Microtubule-associated protein with the capacity to bundle and stabilize microtubules (By similarity). May associate with chromosomes and promote the organization of mitotic spindle microtubules around them. |
| Cellular Location | Cytoplasm. Nucleus, nucleolus. Cytoplasm, cytoskeleton, spindle Chromosome. Note=Found in the cytoplasm and nucleolus during interphase and redistributes to the mitotic spindle in prometaphase (By similarity). Localizes to the mitotic spindle during anaphase and telophase then disappears from around the chromosomes during cytokinesis (By similarity). Localizes to multiple distinct regions of chromosomes throughout mitosis. {ECO:0000250, ECO:0000269|PubMed:17276916, ECO:0000269|PubMed:17618083} |
Research Areas
Application Protocols
Provided below are standard protocols that you may find useful for product applications.
终于等到您。ABCEPTA（百远生物）抗体产品。
点击下方“我要评价 ”按钮提交您的反馈信息，您的反馈和评价是我们最宝贵的财富之一,
我们将在1-3个工作日内处理您的反馈信息。
如有疑问，联系：0512-88856768 tech-china@abcepta.com.
